Imagen de Portada

Commentary on Zhu et al .: Nitazenes—Tracking a moving target from linked United States databases

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Christophe P. Stove, Marthe M. Vandeputte
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Addiction
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Commentary on Pessar et al .: ‘Downscaling’ United States state cannabis policy to investigate environmental and social impacts on cannabis use
por: Jeremy Mennis, et al.
Publicado: (2024)

Commentary on Copeland et al.: Does xylazine in the United Kingdom foreshadow a European synthetic polysubstance drug crisis?
por: Joseph R. Friedman
Publicado: (2024)

Commentary on Aubin et al.: Could combination medication approaches target mental health comorbidity in the context of alcohol use disorder?
por: Shalini Arunogiri, et al.
Publicado: (2024)

Commentary on Getty et al .: Complementarity of harm reduction and contingency management
por: John M. Roll
Publicado: (2026)

Commentary on Serre et al . : Demonstrating the next era of addiction science
por: Bryant M. Stone, et al.
Publicado: (2024)

Commentary on Morris et al .: Shifting consumption from unhealthy to healthy commodities
por: Daniel Araya‐Ríos
Publicado: (2026)

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling
por: Rachel Lees Thorne, et al.
Publicado: (2025)

Commentary on Nieto et al .: The heterogeneity of drug craving and considerations as a treatment endpoint
por: Justin C. Strickland, et al.
Publicado: (2026)

Commentary on Jackson et al.: The role of regional tobacco control in centralised nations
por: Nathan Davies, et al.
Publicado: (2025)

Commentary on Baltes‐Flueckiger et al.: Rethinking expectations and evidence in cannabis policy
por: Sharon R. Sznitman, et al.
Publicado: (2025)

Commentary on Carrasquilla et al.: Smoking and obesity; uncovering causal mechanisms through triangulation of different methods
por: Margot P. van de Weijer, et al.
Publicado: (2024)

Commentary on Ezard et al.: Agonist‐based medications for stimulant use disorder—Distinguishing their true colours
por: Vitor S. Tardelli, et al.
Publicado: (2025)

Commentary on Rehm et al.: Utilizing return on investment analysis to advocate for tax increases
por: Meenakshi S. Subbaraman
Publicado: (2025)

Commentary on Dobbie et al .: Preventing adolescent gambling‐related harm—Is a universal approach sufficient?
por: Jérémie Richard
Publicado: (2026)

Commentary on Giné et al .: The hidden face of overdose: Gender inequities along the continuum of care
por: Patrizia Carrieri, et al.
Publicado: (2025)

Commentary on Stam et al .: The substantial and dynamic contribution of opioid potency to total overdose risk
por: Phillip O. Coffin
Publicado: (2024)

Commentary on Östh et al.: Sensor‐based approaches to inform alcohol interventions – beyond BAC
por: Brian Suffoletto
Publicado: (2025)

Commentary on Andreacchi et al.: Policy responses to shifting epidemiological trends in alcohol use in Canada
por: Carolin Kilian, et al.
Publicado: (2024)

Commentary on Qeadan et al .: Leveraging opportunities to expand the substance use disorder treatment arsenal
por: Ty S. Schepis
Publicado: (2024)

Commentary on Coelho et al .: Ecological momentary assessments may be key to the future of cannabis studies
por: Lucy Chester, et al.
Publicado: (2025)

Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
por: Sandra A. Springer
Publicado: (2024)

Commentary on Craft et al.: Drug contaminants and substitutions in illicit vapes represent a major health risk
por: Caroline S. Copeland
Publicado: (2025)

Commentary on Lim et al .: Real‐world e‐cigarette use under prescription‐only regulation
por: Dimitra Kale, et al.
Publicado: (2026)

Commentary on ter Laak et al .: The importance of drug market information and differentiating drug use patterns
por: Rory Verhagen, et al.
Publicado: (2024)

Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder – an urgent path forward
por: Adam Bisaga
Publicado: (2025)

Commentary on Day et al.: Systemic solutions for recovery support services in Ireland's National Drug Strategy
por: Jo‐Hanna H. Ivers
Publicado: (2025)

Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
por: Nadine Ezard, et al.
Publicado: (2025)

Commentary on Mereish et al .: Supporting sexually diverse youth requires a full spectrum understanding of substance use
por: Kira London‐Nadeau, et al.
Publicado: (2026)

Commentary on He et al .: From static association to dynamic causation ‐ a methodological leap in understanding and addressing addiction
por: Zihan Lv, et al.
Publicado: (2026)

Commentary on Dowd et al .: Beyond single data sources—Consistency checking and evidence synthesis for prevalence estimation
por: Hayley E. Jones, et al.
Publicado: (2026)

Commentary on Amin‐Esmaeili et al .: Non‐abstinence outcomes in stimulant clinical trials—Why deny improvement?
por: Vítor S. Tardelli
Publicado: (2024)

Commentary on Dennett et al .: When heat and the opioid epidemic collide ‐ implications for climate‐resilient public health strategies
por: Tarik Benmarhnia
Publicado: (2025)

Commentary on Bade et al.: Threat of nitazenes and other potent synthetic opioids—Is Europe prepared? Time to respond and to learn
por: Isabelle Giraudon, et al.
Publicado: (2025)

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
por: Jake R. Morgan, et al.
Publicado: (2024)

Commentary on Conde et al.: Evidence and gap map offer an important opportunity for dialogue and refinement of the gateway hypothesis controversy
por: Arielle Selya, et al.
Publicado: (2024)

Commentary on Yang et al.: The need for a renewed focus on identifying and responding to chronic pain among people with substance use disorders
por: Gabrielle Campbell, et al.
Publicado: (2024)

Commentary on Darkeet al.: Expanded psychedelic access requires new safety monitoring systems
por: P. Todd Korthuis, et al.
Publicado: (2024)

Commentary on Metcalfe et al.: ‘What works in AOD is when it feels like I am driving’ (Craig W, alcohol and drug peer worker)
por: Jeremy S. Hayllar
Publicado: (2024)

Psilocybin microdosing in the United States: Insights from a nationally representative survey
por: Michelle Priest, et al.
Publicado: (2026)

Commentary on Piatkowski et al.: Anabolic‐androgenic steroid testing sites are necessary to identify specific anabolic‐androgenic steroid types that are commonly faked putting users at risk
por: Thomas O'Connor
Publicado: (2025)